SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-170662
Filing Date
2017-05-15
Accepted
2017-05-15 16:13:30
Documents
4
Period of Report
2017-05-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d397855d8k.htm 8-K 23763
2 EX-99.1 d397855dex991.htm EX-99.1 16365
3 GRAPHIC g397855g27i03.jpg GRAPHIC 3073
4 GRAPHIC g397855g58b15.jpg GRAPHIC 4504
  Complete submission text file 0001193125-17-170662.txt   52097
Mailing Address 245 FIRST STREET SUITE 1100 CAMBRIDGE MA 02142
Business Address 245 FIRST STREET SUITE 1100 CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 17844351
SIC: 2834 Pharmaceutical Preparations